close

Enter

Log in using OpenID

Acute Heart Failure Therapeutics Market Check Out The Predictions By Experts

embed
The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs.
Acute Heart Failure (AHF) Therapeutics
Market Size, Share, Trend, Outlook, Future
Analysis And Synthesis By 2026
Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump
enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure
is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and
chronic heart failure is important from a clinical standpoint, on which further medication depends. For
this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left
ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute
heart failure compared to those with chronic heart failure patient.
Heart failure symptoms vary widely from person to person, depending on
The main symptoms of heart failure are caused due to fluid accumulation
flow to the body. Symptoms caused by fluid accumulation or congestion
weight gain, coughing, swollen ankles, legs or abdomen, while dizziness,
are symptoms associated with reduced blood flow to parts of the body.
types of heart failure patient.
or congestion and poor blood
includes shortness of breath,
rapid heart rate, and fatigue
Get FREE In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/requestsample/1910
Acute Heart Failure (AHF) Therapeutics Market – Drivers
The global acute heart failure therapeutics market is expected to
approval of new drugs. For instance, in July 2015, Novartis received
(FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on
reduced ejection fraction. Entresto is indicated to reduce the risk
failure hospitalization.
witness significant growth due to
U.S. Food and Drug Administration
the treatment of heart failure with
of cardiovascular death and heart
Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor
driving growth of acute heart failure therapeutics market. For instance, in March 2017,
Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now
operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition
by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase.
CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure
(ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in
future, will help to boost the acute heart failure (AHF) therapeutics market growth during the
forecast period.
Report includes chapters which deeply display the following deliverable about industry :
• Acute Heart Failure (AHF) Therapeutics Market Research Objective and Assumption
• Acute Heart Failure (AHF) Therapeutics Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Acute Heart Failure (AHF) Therapeutics Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Acute Heart Failure (AHF) Therapeutics Market, By Regions
• Acute Heart Failure (AHF) Therapeutics Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Acute Heart Failure (AHF) Therapeutics Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Acute Heart Failure (AHF) Therapeutics Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Acute Heart Failure (AHF) Therapeutics Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis
Geographically, the market is segmented into North America, Latin America, Europe, Middle East, Asia
Pacific, and Africa. North America is expected to hold dominant position in global acute heart failure
(AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region. For
instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million
adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop
heart failure die within 5 years of diagnosis.
Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape
Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb
Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co.,
Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of new drugs
for acute heart failure (AHF). These players are incorporating collaboration strategies to remain
competitive in the market.
Acute Heart Failure (AHF) Therapeutics Market – Taxonomy
By Disorder Type:
•
Right-sided Heart Failure
•
Left-sided Heart Failure: Systolic Failure, Diastolic Failure
•
Congestive Heart Failure
Request For Customization of This Exclusive Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1910
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Poul Master
Poul Master244   documents Email
Document
Category
Health and Medicine
Views
12
File Size
120 KB
Tags
ahf, Acute Heart Failure (AHF) Therapeutics Market
1/--pages
Report inappropriate content